Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Novavax

NVAX

7.9600.13% ( +0.010 )

Closed: Aug 12, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research
Market Beat·Aug 8 at 06:30 AM
NVAX+0.13%
Novavax (NASDAQ:NVAX) Posts Earnings Results, Beats Estimates By $0.06 EPS
Market Beat·Aug 6 at 10:26 PM
NVAX+0.13%
Novavax Slips To Loss In Q2 On Reduced Revenue, Cuts FY26 Guidance
rttnews·Aug 6 at 08:39 AM
NVAX+0.13%
Novavax Q2 2026 earnings: Revenue falls as prior-year payments roll off
TradingKey·Aug 6 at 07:34 AM
NVAX+0.13%
Novavax | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 56.7 M
Earnings Watch·Aug 6 at 07:05 AM
NVAX+0.13%
Novavax Q2 FY26 turns to net loss of $53.39 million; revenue drops 76.29% to $56.7 million
PUBT·Aug 6 at 06:54 AM
NVAX+0.13%SNY+0.34%
These Are the Stocks Reporting Earnings Today – August 6, 2026
Tip Ranks·Aug 6 at 03:30 AM
NVAX+0.13%ROKU+0.58%
Is Novavax’s Pivot To Matrix-M Licensing And Partnership Deals Altering The Investment Case For NVAX?
Simplywall·Aug 5 at 02:26 PM
- Novavax is shifting from direct vaccine sales to a licensing-centric business model centered on its Matrix-M adjuvant technology. - A key development in this transition is the January 2026 agreement with Pfizer, which paid US$ 30.0 million upfront for a non-exclusive global license. - The company's narrative projects US$ 348.5 million in revenue and US$ 55.9 million in earnings by 2028, though risks remain regarding partner dependency.
NVAX+0.13%PFE-1.16%
What To Expect From Novavax’s (NVAX) Q2 Earnings
Stock Story·Aug 4 at 10:28 PM
NVAX+0.13%BIIB+2.44%
Novavax Inc. Stock Outperforms Competitors On Strong Trading Day
MarketWatch Automated·Aug 4 at 04:28 PM
NVAX+0.13%
Novavax Inc. Stock Rises Monday, Still Underperforms Market
MarketWatch Automated·Aug 3 at 04:28 PM
NVAX+0.13%
Novavax Inc. Stock Underperforms Friday When Compared To Competitors
MarketWatch Automated·Jul 31 at 04:27 PM
NVAX+0.13%
Novavax Inc. Stock Rises Thursday, Still Underperforms Market
MarketWatch Automated·Jul 30 at 04:29 PM
NVAX+0.13%
Novavax to report Q2 2026 results, host conference call
PUBT·Jul 30 at 06:19 AM
NVAX+0.13%